



BONESUPPORT's New CEO Purchases Shares

Lund, Sweden, 08.00 CET, 13 March 2018 – BONESUPPORT[™], an emerging leader in innovative injectable bio-ceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery based on its unique CERAMENT[®] platform announces that Emil Billbäck, its recently appointed Chief Executive Officer, purchased 60,000 shares in the Company at a price of SEK 15.07 per share on Friday 9 March.

Björn Westberg, the Company's Chief Financial Officer, bought 20,000 BONESUPPORT shares yesterday at a price of SEK 14.80 per share. Mr Westberg has purchased a total of 60,000 BONESUPPORT shares since the Company's IPO in June 2017. In addition to his shareholding he holds warrants, which he purchased when he joined the Company in early 2017.

About BONESUPPORT™

BONESUPPORT is an innovative and rapidly growing commercial stage orthobiologics company, based in Lund, Sweden. The Company develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs directly into the bone void.

BONESUPPORT's marketed bio-ceramic bone graft substitutes CERAMENT[®] BONE VOID FILLER (BVF), CERAMENT[®] G* and CERAMENT[®] V* are all based on the Company's novel and proprietary CERAMENT technology platform.

The Company's products are targeting a large addressable market opportunity across trauma, chronic osteomyelitis (bone infection), revision arthroplasty (replacement of a joint prosthesis) and infected diabetic foot.

BONESUPPORT's total sales increased from SEK 62 million in 2015 to SEK 129 million in 2017, representing a compound annual growth rate of 45%. The Company's financial target is to achieve revenue exceeding SEK 500 million in the financial year 2020, with a gross margin exceeding 85 percent and a positive operating profit.

The Company's research and development is focused on the continuing development and refinement of its CERAMENT technology to extend its use into additional indications by the elution of other drugs and therapeutic agents. The Company currently has a pipeline of preclinical product candidates that have been designed to promote bone growth.

BONESUPPORT is listed on Nasdaq Stockholm and trades under the ticker "BONEX" (ISIN code: SE0009858152). Further information is available at <u>www.bonesupport.com</u>

*CERAMENT G: Not available in the United States, for investigational use only. CERAMENT V: Not available in the United States

BONESUPPORT[™] and CERAMENT[®] are registered trademarks.



Press Release

For more information contact: Emil Billbäck, CEO +46 (0) 46 286 53 70

Björn Westberg, CFO +46 (0) 46 286 53 60 ir@bonesupport.com

Citigate Dewe Rogerson Pip Batty, David Dible, Shabnam Bashir, Isabelle Andrews +44 (0)20 7282 1022 <u>bonesupport@citigatedewerogerson.com</u>